EUVIMEDDescoperă EUVIMED
Open access · CC BY 4.0

Immune checkpoint CD161 / LLT1 ‐associated immunological landscape and diagnostic value in oral squamous cell carcinoma

Xinyang Hu iD, Yuexin Dong, Shixin Xie, Yuxian Song, Chenhang Yu, Yijia He, Zhiyong Wang, Qingang Hu, Yanhong Ni, Liang Ding iD

The Journal of Pathology: Clinical Research · 2024

DOI: 10.1002/cjp2.353 ↗

At a glance

Journal article in The Journal of Pathology: Clinical Research, 2024. Written by Xinyang Hu and 9 co-authors. Institution: Central Laboratory of Stomatology, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, PR China. Major MEDLINE topics: Carcinoma, Squamous Cell, Head and Neck Neoplasms, Mouth Neoplasms. Cited 12 times so far (Crossref); 40 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province, Nanjing Medical Science and Technology Development Foundation, Nanjing Department of Health.

RezumatSubjectsDate bibliograficeCiteRelated studies

Abstract (original language)

An active host adaptive response is characterized by the existence of programmed cell death protein 1 (PD‐1) + /IFN‐γ + cytotoxic T cells and IFN‐γ‐induced PD‐L1 + tumor cells (TCs), which predicts high response rate to anti‐PD‐1/L1 therapy. Recently, CD161 and its ligand LLT1 (CLEC2D) have been identified as an emerging checkpoint for immunotherapy. Clarifying its heterogeneous clinical expression pattern and its immune landscape is a prerequisite for maximizing the response rate of CD161 blockade therapy in a specific population of oral squamous cell carcinoma (OSCC) patients. Here, we investigated the expression pattern of CD161/LLT1 and its association with major immunocytes (T cells, B cells, NK cells, and macrophages) by multiplex immunofluorescence, immunohistochemistry, and flow cytometry in 109 OSCC tissues and 102 peripheral blood samples. TCs showed higher LLT1 levels than tumor infiltrating lymphocytes (TILs), whereas CD161 was highly expressed in CD8 + T cells at the tumor front, which was decreased in paracancerous tissue. High expression of TC‐derived LLT1 (LLT1 TC ) conferred poor clinical outcomes, whereas higher CD161 + and LLT1 + TILs were associated with better prognosis. Meanwhile, patients with high LLT1 TC showed a decreased ratio of CD8 + /Foxp3 + T cells in situ , but CD161 + TILs correlated with more peripheral CD3 + T cells. Interestingly, treatment of OSCC patients with nivolumab (anti‐PD‐1) could restore tumoral CD161/LLT1 signal. Furthermore, an OSCC subgroup characterized by high LLT1 + TCs and low CD161 + CD8 + T cells showed fewer peripheral T cells and a higher risk of lymph node metastasis, leading to a shorter 5‐year survival time (29%). More LLT1 TC at the invasive front was another risk characteristic of exhausted T cells. In conclusion, in view of this heterogeneity, the LLT1/CD161 distribution pattern should be determined before CD161‐based immunotherapy.

Subjects

MeSH terms (MEDLINE)

Carcinoma, Squamous CellHead and Neck NeoplasmsMouth NeoplasmsHumansCD8-Positive T-LymphocytesSquamous Cell Carcinoma of Head and NeckReceptors, Cell SurfaceLectins, C-TypeNK Cell Lectin-Like Receptor Subfamily B

Author keywords

CD161Foxp3LLT1OSCCPD-1PD-L1T cellsimmune checkpointimmune checkpoint inhibitorsimmunotherapyoral squamous cell carcinoma

Substances

CLEC2D protein, humanReceptors, Cell SurfaceLectins, C-TypeKLRB1 protein, humanNK Cell Lectin-Like Receptor Subfamily B

Authors and institutions

  • Central Laboratory of Stomatology, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, PR China.
  • Department of Oral and Maxillofacial Surgery, Nanjing Stomatological Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, PR China.

ORCID profiles: Xinyang Hu, Liang Ding

Funding

  • National Natural Science Foundation of China
  • Natural Science Foundation of Jiangsu Province
  • Nanjing Medical Science and Technology Development Foundation, Nanjing Department of Health

Cite

APA

Hu, X., Dong, Y., Xie, S., Song, Y., Yu, C., He, Y., Wang, Z., Hu, Q., Ni, Y., & Ding, L. (2024). Immune checkpoint CD161 / LLT1 ‐associated immunological landscape and diagnostic value in oral squamous cell carcinoma. The Journal of Pathology: Clinical Research. https://doi.org/10.1002/cjp2.353

Vancouver

Hu X, Dong Y, Xie S, Song Y, Yu C, He Y, et al. Immune checkpoint CD161 / LLT1 ‐associated immunological landscape and diagnostic value in oral squamous cell carcinoma. The Journal of Pathology: Clinical Research. 2024. doi:10.1002/cjp2.353

BibTeX
@article{Hu2024,
  author = {Hu, Xinyang and Dong, Yuexin and Xie, Shixin and Song, Yuxian and Yu, Chenhang and He, Yijia and Wang, Zhiyong and Hu, Qingang and Ni, Yanhong and Ding, Liang},
  title = {Immune checkpoint CD161 / LLT1 ‐associated immunological landscape and diagnostic value in oral squamous cell carcinoma},
  journal = {The Journal of Pathology: Clinical Research},
  year = {2024},
  doi = {10.1002/cjp2.353}
}
Start for free →